Clinical Trial: NCT04758780
Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Cancer
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Institut Cancerologie de l'Ouest |
| Information Provided By: | Institut Cancerologie de l'Ouest |
| Last Update Posted: | 2026-07-20 |
Study Overview
Brief Summary
The purpose of this study is to evaluate the use of 89Zr-labeled girentuximab (89Zr-TLX250) as a novel, carbonic anhydrase IX (CAIX) targeted PET/CT tracer for the imaging of metastatic triple negative breast cancer (TNBC) patients.
Official Title
Prospective Phase II Pilot Study, Assessing Imaging Performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT (Positron Emission Tomography/Computerized Tomography) in Metastatic Triple Negative Breast Cancer Patients
Conditions
Triple Negative Breast Cancer
Intervention / Treatment
- Drug: 89Zr-TLX250
Other Study ID Numbers
- ICO-2020-25
Start Date (Actual)
2021-09-21
Primary Completion Date (Actual)
2023-03-31
Study Completion Date (Actual)
2023-09-13
Enrollment (Actual)
12
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Institut Cancerologie de l'Ouest |
| Information Provided By: | Institut Cancerologie de l'Ouest |
| Last Update Posted: | 2026-07-20 |
Study Overview
Brief Summary
The purpose of this study is to evaluate the use of 89Zr-labeled girentuximab (89Zr-TLX250) as a novel, carbonic anhydrase IX (CAIX) targeted PET/CT tracer for the imaging of metastatic triple negative breast cancer (TNBC) patients.
Official Title
Prospective Phase II Pilot Study, Assessing Imaging Performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT (Positron Emission Tomography/Computerized Tomography) in Metastatic Triple Negative Breast Cancer Patients
Conditions
Triple Negative Breast Cancer
Intervention / Treatment
- Drug: 89Zr-TLX250
Other Study ID Numbers
- ICO-2020-25
Start Date (Actual)
2021-09-21
Primary Completion Date (Actual)
2023-03-31
Study Completion Date (Actual)
2023-09-13
Enrollment (Actual)
12
Study Type
Interventional
Phase
Phase 2